.svg)
When someone struggles with addiction, there's always more to the story.
They may be battling anxiety that makes it feel impossible to get through the day or depression that makes even getting out of bed feel like a monumental task. For millions of Americans, substance use isn't a moral failing. It is often one component of a broader substance use disorder and underlying mental health conditions.
Treating only the addiction, without addressing the mental health conditions underneath, is like putting a bandage over a wound without cleaning it first.
At Valley Forge Medical Center (VFMC) in Norristown, Pennsylvania, we see this every day. Understanding this connection is important and ultimately can be the difference between life and death.
What Is a Co-Occurring Disorder?
The term "dual diagnosis,” or co-occurring disorder, refers to when a person has both a mental health and substance use disorder at the same time. One of the most effective approaches is integrated treatment for co-occurring disorders, which addresses both conditions simultaneously.
According to the National Institute on Drug Abuse (NIDA), roughly half of adults with a substance use disorder also meet the criteria for a mental health disorder, and vice versa. In 2023 alone, an estimated 20.4 million U.S. adults were living with a dual diagnosis. The two conditions feed each other in a relentless cycle: mental health struggles drive substance use, and substance use worsens mental health. This makes both harder to treat when addressed in isolation.
The most commonly co-occurring mental health conditions include:
- Major Depressive Disorder: People experiencing depression frequently self-medicate with alcohol, opioids, or stimulants to numb emotional pain or boost energy.
- Anxiety Disorders: Alcohol and benzodiazepines are widely misused to quiet anxiety that feels otherwise unmanageable.
- Post-Traumatic Stress Disorder (PTSD): Trauma survivors are at significantly elevated risk for opioid use disorder, particularly when pain (physical or emotional) goes untreated.
- Bipolar Disorder: Substance use rates among people with bipolar disorder are strikingly high, often as a way to manage extreme highs and lows.
- ADHD: Stimulant misuse is common in people with untreated ADHD, who may turn to substances to regulate attention and mood.
The Pennsylvania Crisis in 2026: What We're Seeing on the Ground
Pennsylvania has been one of the hardest-hit states in the national opioid epidemic. The good news: early estimates indicate that Pennsylvania saw the fewest overdose deaths in more than a decade in 2025. This is the result of expanded naloxone distribution, improved treatment access, and sustained community intervention. In that period, the Pennsylvania Department of Drug and Alcohol Programs distributed over 824,000 doses of naloxone and 922,000 fentanyl and xylazine test strips across the state.
Fentanyl and Fentanyl Analogues
Fentanyl remains the single deadliest driver of overdose deaths in Pennsylvania and nationally. According to the United States Drug Enforcement Administration (DEA), 83% of Philadelphia's 2023 overdose deaths involved fentanyl, and it's now being found in nearly every category of street drug, including cocaine and counterfeit pills. Fentanyl is up to 100 times more potent than morphine.
The mental health connection is profound. Fentanyl is frequently used by people managing untreated trauma, chronic pain, and depression. When the mental illness goes unaddressed, relapse rates remain devastating, even after successful detox.
Xylazine ("Tranq") and Medetomidine ("Rhino Tranq")
This is where Pennsylvania's crisis has taken a particularly alarming turn. Xylazine is a veterinary sedative. While it has never been approved for human use, it is being found mixed into the fentanyl supply across the state.
Xylazine does not respond to naloxone. It causes severe, necrotic wounds at injection sites that can require surgical intervention. And withdrawal from xylazine is complex and medically dangerous.
Most recently, a second adulterant has entered the supply: medetomidine, which is commonly known as "rhino tranq.” It is 200 times more potent than xylazine. As of early 2025, medetomidine was found in 87% of Philadelphia drug samples. It causes severe withdrawal symptoms including intractable vomiting, sweating, tremors, and dangerous heart rate elevation that often requires intensive medical intervention.
Treating xylazine and medetomidine involvement isn't something that can happen at home or in a basic outpatient setting. It requires medical detox and often inpatient care.
Alcohol Use Disorder
Alcohol use disorder is the most common and chronically undertreated substance use disorder in Pennsylvania. It's often overlooked because alcohol is legal and socially normalized. However, it carries serious medical risks during withdrawal, including life-threatening seizures. It also has exceptionally high co-occurrence rates with depression and anxiety.
Stimulant Use Disorders (Cocaine & Methamphetamine)
Stimulant use disorder is rising across both urban and suburban Pennsylvania, often presenting alongside ADHD, bipolar disorder, and depression. Many people cycle between stimulants to feel "up" and opioids or alcohol to come down, a pattern that drives rapid physical deterioration.
Why Treating Both Conditions Together Is Critical
For years, the standard approach was to treat mental health and substance use disorders separately. First stabilize the addiction, then address the mental health. Research has shown that this sequential model produces worse outcomes. When only one condition is treated, the untreated condition almost always pulls the person back.
An integrated treatment approach that addresses addiction and mental health simultaneously and produces significantly better outcomes. This type of addiction and mental health treatment allows clinicians to address the full scope of a patient's needs.
- Medical stabilization and safe withdrawal management during detox
- Psychiatric evaluation to identify underlying mental health conditions
- Medication-Assisted Treatment (MAT) using FDA-approved medications like buprenorphine or naltrexone to reduce cravings and support recovery
- Individual therapy, including cognitive behavioral therapy (CBT) and trauma-informed approaches
- Group counseling and peer support from people who have lived through similar experiences
- Aftercare planning to address the full person: housing, mental health follow-up, community support
Without treating the whole picture, recovery is fragile.
How Valley Forge Medical Center Treats the Whole Person
Valley Forge Medical Center is uniquely positioned to treat the most complex, acute cases of co-occurring substance use and mental health disorders. As a hospital-based facility, we provide a level of medical care that goes beyond what most substance abuse treatment centers in PA can offer.
Our multidisciplinary approach includes:
- Medically Supervised Detox: Our 24-hour medical team manages withdrawal safely. You should not attempt to detox from opioids, alcohol, or tranq-adulterated substances without medical oversight.
- Medication-Assisted Treatment (MAT): We use evidence-based MAT protocols for opioid and alcohol use disorder, including buprenorphine.It is medical treatment that dramatically improves outcomes when used as part of a comprehensive recovery plan.
- Wound Care: VFMC provides specialized wound care for severe skin and tissue injuries. This is a critical service that many treatment programs cannot provide.
- Acute Inpatient and Residential Treatment: Our acute inpatient level of care addresses both the medical and psychiatric complexity of co-occurring disorders.
- Individual and Group Counseling: Licensed counselors work with each patient to understand the mental health drivers behind their substance use, develop coping strategies, and rebuild a sustainable life in recovery.
Take the First Step
If you or someone you love is struggling, VFMC is here to help. Our nurses conduct a level-of-care assessment, and our team will walk you through the admissions process step by step. Call or text us today at (610) 539-8500 or visit us online at www.vfmc.net to learn more about our services and start the process.
